PaySign (PAYS)
Market Price (1/22/2026): $4.51 | Market Cap: $247.1 MilSector: Information Technology | Industry: Systems Software
PaySign (PAYS)
Market Price (1/22/2026): $4.51Market Cap: $247.1 MilSector: Information TechnologyIndustry: Systems Software
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 33% | Weak multi-year price returns3Y Excs Rtn is -36% | Key risksPAYS key risks include [1] significant overdependence on its plasma and pharma segments amid recent declines in plasma-related revenue, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 25%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 13% | ||
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -36% | ||
| Megatrend and thematic driversMegatrends include Fintech & Digital Payments. Themes include Digital Payments, and Healthcare Payment Solutions. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 33% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 25%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 13% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -36% |
| Megatrend and thematic driversMegatrends include Fintech & Digital Payments. Themes include Digital Payments, and Healthcare Payment Solutions. |
| Weak multi-year price returns3Y Excs Rtn is -36% |
| Key risksPAYS key risks include [1] significant overdependence on its plasma and pharma segments amid recent declines in plasma-related revenue, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
1. Continued Headwinds in the Plasma Business: PaySign has faced a near-term slowdown in its plasma business due to an industry-wide oversupply of plasma inventories. This has led to a decline in plasma revenue and reduced compensation for donors, with the expectation for this oversupply to abate in the first half of 2026.
2. Negative Technical Signals and Selling Pressure: The stock has displayed "sell signals" from both short and long-term Moving Averages, indicating a negative forecast. A sell signal was issued from a pivot top point on Thursday, December 11, 2025, contributing to a decline of 20.00% since that point.
Show more
Stock Movement Drivers
Fundamental Drivers
The -15.8% change in PAYS stock from 10/31/2025 to 1/21/2026 was primarily driven by a -23.7% change in the company's P/E Multiple.| 10312025 | 1212026 | Change | |
|---|---|---|---|
| Stock Price ($) | 5.17 | 4.35 | -15.8% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 69 | 75 | 9.3% |
| Net Income Margin (%) | 9.9% | 10.1% | 2.0% |
| P/E Multiple | 41.3 | 31.5 | -23.7% |
| Shares Outstanding (Mil) | 54 | 55 | -1.1% |
| Cumulative Contribution | -15.8% |
Market Drivers
10/31/2025 to 1/21/2026| Return | Correlation | |
|---|---|---|
| PAYS | -15.8% | |
| Market (SPY) | 0.5% | 34.5% |
| Sector (XLK) | -4.3% | 20.0% |
Fundamental Drivers
The -41.5% change in PAYS stock from 7/31/2025 to 1/21/2026 was primarily driven by a -51.8% change in the company's P/E Multiple.| 7312025 | 1212026 | Change | |
|---|---|---|---|
| Stock Price ($) | 7.44 | 4.35 | -41.5% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 64 | 75 | 17.4% |
| Net Income Margin (%) | 9.6% | 10.1% | 5.7% |
| P/E Multiple | 65.4 | 31.5 | -51.8% |
| Shares Outstanding (Mil) | 54 | 55 | -2.3% |
| Cumulative Contribution | -41.6% |
Market Drivers
7/31/2025 to 1/21/2026| Return | Correlation | |
|---|---|---|
| PAYS | -41.5% | |
| Market (SPY) | 8.7% | 19.9% |
| Sector (XLK) | 9.6% | 12.5% |
Fundamental Drivers
The 63.5% change in PAYS stock from 1/31/2025 to 1/21/2026 was primarily driven by a 78.8% change in the company's P/E Multiple.| 1312025 | 1212026 | Change | |
|---|---|---|---|
| Stock Price ($) | 2.66 | 4.35 | 63.5% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 56 | 75 | 32.6% |
| Net Income Margin (%) | 14.3% | 10.1% | -29.3% |
| P/E Multiple | 17.6 | 31.5 | 78.8% |
| Shares Outstanding (Mil) | 53 | 55 | -2.5% |
| Cumulative Contribution | 63.4% |
Market Drivers
1/31/2025 to 1/21/2026| Return | Correlation | |
|---|---|---|
| PAYS | 63.5% | |
| Market (SPY) | 14.9% | 34.9% |
| Sector (XLK) | 25.2% | 34.0% |
Fundamental Drivers
The 25.4% change in PAYS stock from 1/31/2023 to 1/21/2026 was primarily driven by a 770.3% change in the company's Net Income Margin (%).| 1312023 | 1212026 | Change | |
|---|---|---|---|
| Stock Price ($) | 3.47 | 4.35 | 25.4% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 36 | 75 | 106.9% |
| Net Income Margin (%) | 1.2% | 10.1% | 770.3% |
| P/E Multiple | 431.0 | 31.5 | -92.7% |
| Shares Outstanding (Mil) | 52 | 55 | -5.1% |
| Cumulative Contribution | 25.0% |
Market Drivers
1/31/2023 to 1/21/2026| Return | Correlation | |
|---|---|---|
| PAYS | 25.4% | |
| Market (SPY) | 74.9% | 31.7% |
| Sector (XLK) | 115.9% | 26.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PAYS Return | -66% | 61% | 9% | 8% | 71% | -14% | -5% |
| Peers Return | -27% | -21% | 7% | 16% | -22% | -5% | -47% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 81% |
Monthly Win Rates [3] | |||||||
| PAYS Win Rate | 17% | 42% | 50% | 33% | 50% | 0% | |
| Peers Win Rate | 37% | 47% | 58% | 58% | 47% | 20% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 0% | |
Max Drawdowns [4] | |||||||
| PAYS Max Drawdown | -69% | -23% | -34% | -11% | -36% | -14% | |
| Peers Max Drawdown | -33% | -32% | -17% | -13% | -42% | -5% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: GDOT, FISV, FIS, WEX, GPN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/21/2026 (YTD)
How Low Can It Go
| Event | PAYS | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -77.4% | -25.4% |
| % Gain to Breakeven | 342.7% | 34.1% |
| Time to Breakeven | 1,138 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -61.9% | -33.9% |
| % Gain to Breakeven | 162.3% | 51.3% |
| Time to Breakeven | 94 days | 148 days |
| 2018 Correction | ||
| % Loss | -50.6% | -19.8% |
| % Gain to Breakeven | 102.6% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -98.9% | -56.8% |
| % Gain to Breakeven | 9400.0% | 131.3% |
| Time to Breakeven | 3,332 days | 1,480 days |
Compare to GDOT, FISV, FIS, WEX, GPN
In The Past
PaySign's stock fell -77.4% during the 2022 Inflation Shock from a high on 2/8/2021. A -77.4% loss requires a 342.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Green Dot for businesses and healthcare: PaySign issues and manages prepaid debit card programs, similar to how Green Dot offers consumer prepaid cards, but with a significant focus on corporate incentives and patient affordability programs (copay assistance) for the healthcare industry.
A specialized Stripe for healthcare payments: Just as Stripe provides payment processing infrastructure for various online businesses, PaySign offers a similar backend platform specifically designed for managing and processing payments for patient copay assistance and other incentive programs in the healthcare sector.
AI Analysis | Feedback
- Patient Reimbursement Programs: Specialized prepaid card solutions for pharmaceutical companies and contract research organizations (CROs) to manage patient financial assistance and clinical trial reimbursements.
- Payroll Card Programs: Prepaid debit card programs that enable employers to efficiently disburse wages to their employees, often serving the unbanked or underbanked population.
- Incentive & Rewards Programs: Prepaid card solutions designed for corporate incentives, customer loyalty, promotional giveaways, and employee recognition.
- General Purpose Reloadable (GPR) Programs: Provides platforms for financial institutions and businesses to offer reloadable prepaid debit cards to consumers as an alternative to traditional bank accounts.
AI Analysis | Feedback
PaySign (PAYS) primarily sells its payment solutions and prepaid card programs to other companies, making it a Business-to-Business (B2B) entity.
According to PaySign's latest Annual Report on Form 10-K (e.g., for the fiscal year ended December 31, 2023), the company explicitly states that it has no individual customer that accounted for 10% or more of its total revenues for the reported periods. This means that PaySign does not have a single "major customer" as typically defined by SEC reporting thresholds requiring specific disclosure.
However, PaySign serves various categories of businesses that utilize its payment solutions. These categories represent its key customer segments:
- Pharmaceutical Companies: PaySign provides co-pay and patient assistance programs, enabling pharmaceutical companies to manage payments for patient support, rebates, and incentives.
- Plasma Collection Centers/Organizations: The company offers specialized payment solutions for the plasma industry, facilitating efficient disbursements to plasma donors.
- Corporations Across Various Industries: Many businesses use PaySign's platform for corporate incentive programs, rebates, rewards, and other disbursement needs, leveraging prepaid cards for employee recognition, consumer promotions, and more.
Since no individual customer meets the threshold for major customer disclosure, specific names of customer companies are not publicly identified by PaySign in its financial filings.
AI Analysis | Feedback
- Visa Inc. (V)
- Mastercard Incorporated (MA)
- Metropolitan Bank Holding Corp. (MCB)
- The Bancorp, Inc. (TBBK)
- Pathward Financial, Inc. (CASH)
- Axiom Bank N.A.
AI Analysis | Feedback
Mark R. Newcomer, President, CEO, and Chairman
Mark Newcomer co-founded PaySign, Inc., (formerly known as 3Pea International, Inc.) and has served as its President since January 2024 and Chief Executive Officer since March 2006. He also holds the position of Chairman of the Board. Prior to PaySign, he co-founded 3PEA Technologies, Inc. in 2001, where he continues to serve as Chairman and CEO. Mr. Newcomer studied Bio-Science at Cal-Poly San Luis Obispo, and under his leadership, PaySign has achieved significant growth through strategic investments, acquisitions, new product introductions, and strong partnerships.
Mark Attinger, Chief Financial Officer and Treasurer
Mark Attinger serves as PaySign's Chief Financial Officer and Treasurer.
Matthew Louis Lanford, Chief Payments Officer and Director
Matthew Lanford was appointed Chief Payments Officer in January 2024. He previously served as President and Chief Operating Officer, a role he was named to in February 2021. With over 30 years of experience in the payments industry, Mr. Lanford's career includes significant roles at various companies. He held positions at Citigroup, including Vice President of Business Development and Director of Corporate Investment Bank Global Transaction Services. He also worked internationally with Euronet Worldwide, Inc., and served as SVP and General Manager of the Financial Services division of InComm. At MasterCard, he held various roles in product management and strategy development, including SVP-ESS, Processing and Network Solutions Lead, North America, and Prepaid Product Lead for Europe. Mr. Lanford was recognized as the "Most Influential Figure in European Prepaid Industry" in the Prepaid Power 10.
Cosimo Cambi, Chief Operating Officer
Cosimo Cambi was appointed Chief Operating Officer of PaySign in January 2024. He joined the company in 2021 as Director of Data Science and was promoted to Vice President of Operations in 2022. Before joining PaySign, Mr. Cambi spent nine years (2012-2021) at Mercalis, Inc. (formerly TrialCard Incorporated), gaining extensive experience in the patient affordability space, progressing from Project Manager to Director of Service Operations. His career also includes serving as an Officer in the United States Coast Guard. Mr. Cambi holds a Bachelor of Science in Operations Research and Computer Analysis from the Coast Guard Academy and a Master of Professional Studies in Analytics from Northeastern University.
Robert P. Strobo, General Counsel, Chief Legal Officer, and Secretary
Robert P. Strobo holds the titles of General Counsel, Chief Legal Officer, and Secretary at PaySign.
AI Analysis | Feedback
Here are the key risks to PaySign's (PAYS) business:
- Reliance on Plasma and Pharma Patient Affordability Segments & Market Challenges: PaySign's business is significantly dependent on its plasma and pharma patient affordability segments. Overdependence on these specific reimbursement segments, coupled with potential customer concentration, creates significant vulnerability to revenue and margin disruption. The prepaid card market, a core area for PaySign, has also experienced an overall decline in recent years, which could threaten parts of the company's core operations. Furthermore, recent reports indicate a decrease in plasma revenue, primarily due to reduced revenue per plasma center, plasma donations, and dollars loaded to cards. The company also faces the risk of increased competition in both the plasma and pharma sectors, potentially leading to slower growth or reduced margins.
- Regulatory and Compliance Risks: Operating in the highly regulated fintech and healthcare payment environment exposes PaySign to substantial regulatory and compliance risks. Failure by the company or its business partners to adhere to applicable laws, regulations, credit card association rules, or other industry standards could have an adverse effect on its business, financial condition, profitability, and cash flows. Non-compliance with payment regulations, such as PCI DSS and data privacy regulations like GDPR and CCPA, can lead to significant fines, legal action, and damage to the company's reputation.
- Cybersecurity, Data Breaches, and Fraud: PaySign faces inherent risks related to cybersecurity, data breaches, and fraud, which are critical challenges in the payment processing industry. A data security breach could expose the company to liability and protracted, costly litigation. In March 2024, PaySign launched an investigation into claims that one of its databases, reportedly containing over 1.2 million consumer records, had been compromised in a data breach and leaked on a hacking forum. Data breaches can lead to financial loss, damage to reputation, and regulatory penalties.
AI Analysis | Feedback
The increasing adoption and expansion of real-time payment networks (such as FedNow and The Clearing House’s RTP network in the US) combined with the proliferation of instant payout solutions offered by fintechs. These systems enable businesses to disburse funds directly and instantly into recipients' bank accounts, providing a direct alternative to certain use cases currently served by PaySign's prepaid card programs, particularly for corporate incentives, payouts, and some forms of disbursements. While prepaid cards offer specific advantages in program management, control, and accessibility for the unbanked, the growing preference for immediate and direct bank transfers could erode demand for some of PaySign’s offerings, especially where speed and direct deposit are the primary requirements.
AI Analysis | Feedback
PaySign (PAYS) primarily offers prepaid card programs, patient affordability offerings, and plasma donor compensation solutions.
Prepaid Card Programs
- Global Market:
- The global prepaid card market was valued at $2.8 trillion in 2023 and is projected to reach $5.8 trillion by 2033, growing at a CAGR of 7.3% from 2024 to 2033.
- Another estimate states the global prepaid card market size was $3.53 trillion in 2023 and is expected to reach approximately $11.39 trillion by 2030, with a CAGR of 18.2% from 2024 to 2030.
- Further estimates place the global prepaid card market at $96.46 billion in 2024, projected to reach $161.79 billion by 2032 with a CAGR of 6.67%. Yet another source estimates the global market at $3.60 billion in 2024, projected to reach $21.46 billion by 2034 with a CAGR of 19.54%.
- U.S. Market:
- The U.S. prepaid card market size was valued at $1.76 trillion in 2024 and is projected to reach approximately $10.62 trillion by 2034, with a CAGR of 19.69% from 2025 to 2034.
- Another report indicates the U.S. prepaid card market was valued at $320 billion in 2024 and is expected to exceed $575 billion by 2033, growing at a CAGR of 7.3%.
Patient Affordability Programs (Healthcare/Pharmaceutical)
- Global Market:
- The global patient support programs market size was valued at $8.4 billion in 2024 and is forecasted to reach $19.7 billion by 2033, with a CAGR of 10.2%.
- The Global Patient Support Programs (PSP) Market is estimated to be valued at $22.70 billion in 2025 and is expected to reach $68.95 billion by 2032, exhibiting a CAGR of 17.2% from 2025 to 2032.
- Another estimate valued the Global Patient Support Programs (PSP) Market at $16.41 billion in 2022, with an expectation to reach $64.36 billion by 2031 at a CAGR of 16.62%.
- The global pharma hub and patient access support service market size was estimated at $3.0 billion in 2023 and is projected to reach $5.7 billion by 2030, growing at a CAGR of 9.9% from 2024 to 2030.
- PaySign's Specific Addressable Market (U.S.):
- PaySign's patient affordability segment has a total addressable market (TAM) estimated to be in the order of $500 million.
Plasma Donor Compensation Solutions
- Market Size: null. While PaySign is a dominant player, controlling approximately 50% of the plasma donation center market, a specific overall market size in USD for plasma donor compensation was not identified.
AI Analysis | Feedback
PaySign (PAYS) is anticipated to drive future revenue growth through several key initiatives and market trends over the next 2-3 years:
-
Continued Expansion of Pharma Patient Affordability Programs: This segment has been a significant growth engine for PaySign, with revenue increasing by 189.9% year-over-year in Q2 2025 and 261% in Q1 2025. The company expects its pharma revenue to at least double in fiscal year 2025. This growth is fueled by the launch of new pharma affordability programs, higher claim volumes, and the acquisition of new customers, including larger pharmaceutical programs. PaySign's proprietary AI-driven analytics, which detect copay maximizer fraud with high accuracy, further enhance its value proposition to pharmaceutical clients. This segment also contributes to improved gross margins for the company.
-
Strategic Growth and SaaS Solutions in the Plasma Industry: Although the plasma business has faced some headwinds, PaySign continues to expand its market share by onboarding new plasma centers. A significant driver for future revenue in this sector is the acquisition of Gamma Innovation in 2024, which introduces high-margin Software-as-a-Service (SaaS) solutions. These include a donor engagement app designed to reduce labor costs and improve donor retention for plasma centers, expanding PaySign's market potential and creating new revenue streams within this maturing business segment.
-
Diversification into New Verticals and Prepaid Products: PaySign is strategically expanding beyond its core pharma and plasma offerings into new verticals. Its "Other" revenue category, which includes retail, payroll, and other prepaid products, showed a 51.4% year-over-year increase in Q2 2025, indicating successful diversification efforts. The company is also targeting growth in areas such as corporate rewards, prepaid gift cards, healthcare reimbursements, and clinical trials, positioning itself for long-term revenue diversification.
-
Increased Revenue Per Pharma Program and Customer Wins: The average revenue per pharma patient affordability program nearly doubled from Q2 2024 to Q2 2025, increasing from $43,851 to $79,937. This demonstrates PaySign's ability to attract and secure larger and more lucrative programs from existing and new customers within the pharmaceutical sector, indicating strong customer satisfaction and competitive advantage.
AI Analysis | Feedback
Share Repurchases
- PaySign's Board of Directors authorized a new stock repurchase program of up to $5,000,000 on March 21, 2023, expected to be completed over the next 36 months.
- In Q3 2024, PaySign repurchased 100,000 shares for $360,000.
- As of Q3 2024, $3.5 million remained authorized under the share repurchase program.
Outbound Investments
- PaySign acquired Gamma Innovation LLC, announced on May 8, 2025, to enhance its capabilities in plasma donor and pharmaceutical patient engagement.
- Annual cash cost savings from the Gamma acquisition are expected to be at the high end of $4 million to $5 million.
Capital Expenditures
- Capital expenditures for the last 12 months were approximately -$403,688.
- Major investments in capital expenditures have been focused on developing the Pharma business over the last few years.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| PaySign Earnings Notes | 12/16/2025 | |
| How Low Can PaySign Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for PaySign
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 63.16 |
| Mkt Cap | 11.5 |
| Rev LTM | 6,544 |
| Op Inc LTM | 1,198 |
| FCF LTM | 1,211 |
| FCF 3Y Avg | 671 |
| CFO LTM | 1,715 |
| CFO 3Y Avg | 1,175 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 13.1% |
| Rev Chg 3Y Avg | 6.8% |
| Rev Chg Q | 4.8% |
| QoQ Delta Rev Chg LTM | 1.2% |
| Op Mgn LTM | 18.2% |
| Op Mgn 3Y Avg | 18.0% |
| QoQ Delta Op Mgn LTM | -0.6% |
| CFO/Rev LTM | 27.6% |
| CFO/Rev 3Y Avg | 26.7% |
| FCF/Rev LTM | 19.4% |
| FCF/Rev 3Y Avg | 16.7% |
Price Behavior
| Market Price | $4.35 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 02/23/2007 | |
| Distance from 52W High | -49.2% | |
| 50 Days | 200 Days | |
| DMA Price | $5.12 | $5.13 |
| DMA Trend | up | down |
| Distance from DMA | -15.1% | -15.2% |
| 3M | 1YR | |
| Volatility | 40.0% | 69.3% |
| Downside Capture | 252.49 | 154.06 |
| Upside Capture | 91.29 | 174.83 |
| Correlation (SPY) | 38.6% | 34.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.76 | 1.22 | 1.51 | 1.04 | 1.21 | 1.31 |
| Up Beta | -0.31 | -0.50 | 0.83 | 0.31 | 0.81 | 1.16 |
| Down Beta | -0.09 | -0.73 | 0.55 | 1.29 | 1.13 | 1.23 |
| Up Capture | 278% | 252% | 150% | 35% | 287% | 314% |
| Bmk +ve Days | 11 | 23 | 37 | 72 | 143 | 431 |
| Stock +ve Days | 10 | 18 | 28 | 57 | 121 | 363 |
| Down Capture | 269% | 217% | 237% | 165% | 125% | 108% |
| Bmk -ve Days | 11 | 18 | 27 | 55 | 108 | 320 |
| Stock -ve Days | 10 | 20 | 33 | 63 | 118 | 357 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PAYS | |
|---|---|---|---|---|
| PAYS | 34.6% | 69.2% | 0.72 | - |
| Sector ETF (XLK) | 23.5% | 27.4% | 0.75 | 32.8% |
| Equity (SPY) | 15.8% | 19.3% | 0.63 | 34.7% |
| Gold (GLD) | 79.5% | 20.4% | 2.78 | 1.9% |
| Commodities (DBC) | 5.7% | 15.3% | 0.16 | 6.4% |
| Real Estate (VNQ) | 5.8% | 16.7% | 0.17 | 28.2% |
| Bitcoin (BTCUSD) | -14.7% | 39.8% | -0.31 | 18.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PAYS | |
|---|---|---|---|---|
| PAYS | -3.3% | 65.2% | 0.22 | - |
| Sector ETF (XLK) | 18.1% | 24.7% | 0.66 | 33.9% |
| Equity (SPY) | 14.0% | 17.1% | 0.66 | 36.4% |
| Gold (GLD) | 20.8% | 15.7% | 1.07 | 5.5% |
| Commodities (DBC) | 11.4% | 18.7% | 0.49 | 9.3% |
| Real Estate (VNQ) | 5.7% | 18.8% | 0.21 | 27.7% |
| Bitcoin (BTCUSD) | 19.0% | 58.0% | 0.53 | 16.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PAYS | |
|---|---|---|---|---|
| PAYS | 0.9% | 73.6% | 0.34 | - |
| Sector ETF (XLK) | 22.9% | 24.2% | 0.86 | 29.8% |
| Equity (SPY) | 15.3% | 18.0% | 0.73 | 32.8% |
| Gold (GLD) | 15.7% | 14.9% | 0.87 | 4.3% |
| Commodities (DBC) | 8.2% | 17.6% | 0.38 | 13.1% |
| Real Estate (VNQ) | 5.8% | 20.8% | 0.25 | 27.9% |
| Bitcoin (BTCUSD) | 70.3% | 66.7% | 1.09 | 11.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/12/2025 | 0.0% | -5.9% | -2.0% |
| 8/5/2025 | -26.7% | -23.6% | -26.4% |
| 3/25/2025 | -8.5% | -14.5% | -2.8% |
| 11/5/2024 | 6.0% | 0.5% | -12.0% |
| 7/31/2024 | -8.6% | -16.9% | -11.4% |
| 3/26/2024 | 18.3% | 32.2% | 29.6% |
| 11/7/2023 | 13.5% | 19.8% | 13.5% |
| 8/8/2023 | 7.6% | 4.9% | 17.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 8 | 7 |
| # Negative | 10 | 10 | 11 |
| Median Positive | 6.8% | 12.3% | 18.5% |
| Median Negative | -14.0% | -17.7% | -12.0% |
| Max Positive | 18.3% | 32.2% | 31.7% |
| Max Negative | -31.6% | -32.4% | -45.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/13/2025 | 10-Q (09/30/2025) |
| 06/30/2025 | 08/06/2025 | 10-Q (06/30/2025) |
| 03/31/2025 | 05/09/2025 | 10-Q (03/31/2025) |
| 12/31/2024 | 03/26/2025 | 10-K (12/31/2024) |
| 09/30/2024 | 11/06/2024 | 10-Q (09/30/2024) |
| 06/30/2024 | 08/01/2024 | 10-Q (06/30/2024) |
| 03/31/2024 | 05/08/2024 | 10-Q (03/31/2024) |
| 12/31/2023 | 03/27/2024 | 10-K (12/31/2023) |
| 09/30/2023 | 11/08/2023 | 10-Q (09/30/2023) |
| 06/30/2023 | 08/09/2023 | 10-Q (06/30/2023) |
| 03/31/2023 | 05/11/2023 | 10-Q (03/31/2023) |
| 12/31/2022 | 03/22/2023 | 10-K (12/31/2022) |
| 09/30/2022 | 11/09/2022 | 10-Q (09/30/2022) |
| 06/30/2022 | 08/10/2022 | 10-Q (06/30/2022) |
| 03/31/2022 | 05/12/2022 | 10-Q (03/31/2022) |
| 12/31/2021 | 03/23/2022 | 10-K (12/31/2021) |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Strobo, Robert | Chief Legal Officer | Direct | Sell | 12122025 | 5.47 | 20,000 | 109,400 | 1,790,276 | Form |
| 2 | Newcomer, Mark | CEO | Direct | Sell | 8042025 | 7.09 | 62,158 | 440,396 | 61,999,783 | Form |
| 3 | Strobo, Robert | Chief Legal Officer | Direct | Sell | 8042025 | 7.09 | 26,521 | 187,904 | 1,752,074 | Form |
| 4 | Herman, Joan M | EVP, Operations | Direct | Sell | 8042025 | 7.09 | 14,160 | 100,325 | 5,820,998 | Form |
| 5 | Baker, Jeffery Bradford | Chief Financial Officer | Direct | Sell | 8042025 | 7.09 | 30,396 | 215,359 | 1,787,379 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.